Physician profile

Moses Bulambo

Psychiatry · Lovington, NM

NPI 1104410331

$1,628.77

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$917.43
Food and Beverage$575.44

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Neuronetics, INC. $1,429.64 2023 Neurostar Tms Therapy System
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $46.91 2021
Alkermes, INC. $45.75 2023 Lybalvi, Aristada
Abbvie INC. $45.05 2022-2024
Teva Pharmaceuticals USA, INC. $33.78 2022
Lundbeck LLC $14.43 2022
Otsuka America Pharmaceutical, INC. $13.21 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Moses Bulambo

$1,628.77

in general payments reported 2019-2025

Years
2021-2024
Top company
Neuronetics, INC.

https://glasscript.com/doctor/9386252/moses-bulambo

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.